Last 12 months
Inside the activity.
0 purchase rows · 38 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 22 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2021 Filed Feb 18, 2021 22:26 UTC |
Friedman Mark LouisVP, Regulatory & Quality
|
GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000028 · wf-form4_161368718486832.xml · nonDerivative · entry 3 Friedman Mark Louis · CIK 0001531023 · VP, Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,297 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:26 UTC |
Friedman Mark LouisVP, Regulatory & Quality
|
GrantCommon Stock | 1,930 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000028 · wf-form4_161368718486832.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP, Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,706 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:26 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000027 · wf-form4_161368715401383.xml · nonDerivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,404 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:26 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
GrantCommon Stock | 5,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000027 · wf-form4_161368715401383.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,765 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:25 UTC |
Sandberg EricChief Commercial Officer
|
GrantCommon Stock | 2,531 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000026 · wf-form4_161368713357992.xml · nonDerivative · entry 1 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,126 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:17 UTC |
Donovan Michael PatrickVP Operations
|
GrantCommon Stock | 675 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000025 · wf-form4_161368661151954.xml · nonDerivative · entry 3 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,854 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:17 UTC |
Donovan Michael PatrickVP Operations
|
GrantCommon Stock | 1,930 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000025 · wf-form4_161368661151954.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,769 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:16 UTC |
Freitag Gregory GeneDirector
|
GrantCommon Stock | 1,784 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000024 · wf-form4_161368656384787.xml · nonDerivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,897 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:16 UTC |
Freitag Gregory GeneDirector
|
GrantCommon Stock | 3,377 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000024 · wf-form4_161368656384787.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,145 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:15 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
GrantCommon Stock | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000023 · wf-form4_161368653976675.xml · nonDerivative · entry 1 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,990 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:15 UTC |
MARIANI PETER JChief Financial Officer
|
GrantCommon Stock | 3,157 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000022 · wf-form4_161368651610562.xml · nonDerivative · entry 3 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,023 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:15 UTC |
MARIANI PETER JChief Financial Officer
|
GrantCommon Stock | 7,655 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000022 · wf-form4_161368651610562.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,031 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:15 UTC |
Zaderej Karen L.Director · CEO
|
GrantCommon Stock | 13,978 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000021 · wf-form4_161368648138970.xml · nonDerivative · entry 3 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,916 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:15 UTC |
Zaderej Karen L.Director · CEO
|
GrantCommon Stock | 16,021 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000021 · wf-form4_161368648138970.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,120 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:14 UTC |
Billet IsabelleChief Strategy and BD Officer
|
GrantCommon Stock | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000020 · wf-form4_161368645399853.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,534 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:12 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 20,000 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0000805928-21-000005 · wf-form4_161291589737508.xml · derivative · entry 3 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on September 22, 2019 (4 years from the option grant date). Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:12 UTC |
Donovan Michael PatrickVP Operations
|
Tax withholdingCommon Stock | 5,190 | $19.81 | $102,813.90 |
DisclosureSEC source: 0000805928-21-000005 · wf-form4_161291589737508.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,839 F2 · shares: Represents the number of shares swapped to cover the exercise price of the options exercised via an attestation method stock swap in accordance with Rule16b-3. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:12 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionCommon Stock | 20,000 | $5.14 | $102,800.00 |
DisclosureSEC source: 0000805928-21-000005 · wf-form4_161291589737508.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: All shares of Common Stock underlying the employee stock option became fully vested on September 22, 2019 (4 years from the option grant date). Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:08 UTC |
Zaderej Karen L.Director · CEO
|
SaleCommon Stock | 65,000 | $20.00 | $1,300,000.00 |
DisclosureSEC source: 0001179110-21-000537 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,099 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2020. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:06 UTC |
Donovan Michael PatrickVP Operations
|
SaleCommon Stock | 1,733 | $17.48 | $30,292.84 |
DisclosureSEC source: 0001179110-20-012342 · edgar.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,029 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2020. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 21:09 UTC |
Donovan Michael PatrickVP Operations
|
SaleCommon Stock | 567 | $17.81 | $10,098.27 |
DisclosureSEC source: 0001179110-20-012297 · edgar.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,762 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 22:33 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
SaleCommon Stock | 371 | $17.81 | $6,607.51 |
DisclosureSEC source: 0001179110-20-012325 · edgar.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,240 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 17:53 UTC |
Freitag Gregory GeneDirector
|
SaleCommon Stock | 916 | $17.81 | $16,313.96 |
DisclosureSEC source: 0001179110-20-012293 · edgar.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,345 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:56 UTC |
MARIANI PETER JChief Financial Officer
|
SaleCommon Stock | 1,293 | $17.81 | $23,028.33 |
DisclosureSEC source: 0001179110-20-012288 · edgar.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,376 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:55 UTC |
Scopelianos AngeloVP Research & Development
|
SaleCommon Stock | 567 | $17.81 | $10,098.27 |
DisclosureSEC source: 0001179110-20-012287 · edgar.xml · nonDerivative · entry 2 Scopelianos Angelo · CIK 0001751541 · VP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,529 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:53 UTC |
Zaderej Karen L.Director · CEO
|
SaleCommon Stock | 3,500 | $17.81 | $62,335.00 |
DisclosureSEC source: 0001179110-20-012286 · edgar.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 674,099 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:52 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
SaleCommon Stock | 567 | $17.81 | $10,098.27 |
DisclosureSEC source: 0001179110-20-012285 · edgar.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,124 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:51 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
SaleCommon Stock | 567 | $17.81 | $10,098.27 |
DisclosureSEC source: 0001179110-20-012284 · edgar.xml · nonDerivative · entry 2 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,665 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:51 UTC |
Billet IsabelleChief Strategy and BD Officer
|
SaleCommon Stock | 649 | $17.81 | $11,558.69 |
DisclosureSEC source: 0001179110-20-012283 · edgar.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,496 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 21:09 UTC |
Donovan Michael PatrickVP Operations
|
GrantCommon Stock | 2,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012297 · edgar.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,329 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 22:33 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
GrantCommon Stock | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012325 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,611 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 17:53 UTC |
Freitag Gregory GeneDirector
|
GrantCommon Stock | 2,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012293 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,261 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. F3 · balance_after: Includes 1885 shares acquired under the Axogen, Inc. employee stock purchase plan on June 30, 2020. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 16:56 UTC |
MARIANI PETER JChief Financial Officer
|
GrantCommon Stock | 5,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012288 · edgar.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,669 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 16:55 UTC |
Scopelianos AngeloVP Research & Development
|
GrantCommon Stock | 2,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012287 · edgar.xml · nonDerivative · entry 1 Scopelianos Angelo · CIK 0001751541 · VP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,096 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. F3 · balance_after: Includes 1547 shares acquired under the Axogen, Inc. employee stock purchase plan on June 30, 2020. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 16:53 UTC |
Zaderej Karen L.Director · CEO
|
GrantCommon Stock | 8,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012286 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 677,599 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. F3 · balance_after: Includes 2705 shares acquired under the Axogen, Inc. employee stock purchase plan on June 30, 2020. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 16:52 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
GrantCommon Stock | 2,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012285 · edgar.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,691 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. F3 · balance_after: Includes 498 shares acquired under the Axogen, Inc. employee stock purchase plan on June 30, 2020. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 16:51 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
GrantCommon Stock | 2,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012284 · edgar.xml · nonDerivative · entry 1 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,232 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 16:51 UTC |
Billet IsabelleChief Strategy and BD Officer
|
GrantCommon Stock | 2,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012283 · edgar.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,145 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. F3 · balance_after: Includes 1324 shares acquired under the Axogen, Inc. employee stock purchase plan on June 30, 2020. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 14:26 UTC |
Zaderej Karen L.Director · CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 19,375 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001179110-20-012230 · edgar.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,375 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 14:26 UTC |
Zaderej Karen L.Director · CEO
|
Exercise / conversionCommon Stock | 19,375 | $4.81 | $93,193.75 |
DisclosureSEC source: 0001179110-20-012230 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 19:32 UTC |
Donovan Michael PatrickVP Operations
|
SaleCommon Stock | 279 | $17.19 | $4,796.01 |
DisclosureSEC source: 0001179110-20-012213 · edgar.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,029 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2020. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 22:32 UTC |
Zaderej Karen L.Director · CEO
|
SaleCommon Stock | 1,275 | $16.42 | $20,935.50 |
DisclosureSEC source: 0001179110-20-012189 · edgar.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,719 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 18, 2020. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 20:22 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
SaleCommon Stock | 147 | $16.42 | $2,413.74 |
DisclosureSEC source: 0001179110-20-012175 · edgar.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,111 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 18, 2020. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 20:15 UTC |
Freitag Gregory GeneDirector
|
SaleCommon Stock | 379 | $16.42 | $6,223.18 |
DisclosureSEC source: 0001179110-20-012171 · edgar.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,076 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 18, 2020. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 18:55 UTC |
Donovan Michael PatrickVP Operations
|
SaleCommon Stock | 96 | $16.42 | $1,576.32 |
DisclosureSEC source: 0001179110-20-012169 · edgar.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,308 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 18, 2020. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 17:54 UTC |
MARIANI PETER JChief Financial Officer
|
SaleCommon Stock | 481 | $16.42 | $7,898.02 |
DisclosureSEC source: 0001179110-20-012162 · edgar.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,419 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 18, 2020. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 16:38 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
SaleCommon Stock | 96 | $16.42 | $1,576.32 |
DisclosureSEC source: 0001179110-20-012160 · edgar.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,893 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 18, 2020. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 22:32 UTC |
Zaderej Karen L.Director · CEO
|
GrantCommon Stock | 3,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012189 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,994 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2020. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 20:22 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
GrantCommon Stock | 575 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012175 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,258 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2020. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 20:15 UTC |
Freitag Gregory GeneDirector
|
GrantCommon Stock | 925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012171 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,455 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.